Status:
RECRUITING
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Lead Sponsor:
Sherief Abd-Elsalam
Conditions:
Beta Blocker Toxicity
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Detailed Description
Clinical study evaluating selective or nonselective beta blockers use and if there is fracture risk in patients with primary osteoporosis
Eligibility Criteria
Inclusion
- • Male \& female osteoporotic patient aged ≥ 50 years
- Hypertensive \& normotensive patients
- BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion
- Patients on drugs that may improve osteoporosis disease state such as:
- Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.
- Patients on drugs that may worsen osteoporosis disease state such as:
- • Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04704947
Start Date
October 1 2017
End Date
October 1 2030
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Tanta, Egypt, 35127